SecBot SecBot

BKHAU

Black Hawk Acquisition Corp
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0002000775 Biotech & Drug Discovery
Units of Black Hawk Acquisition Corp · BKHA stock page →
$5.24 +1.22 (+30.35%)
Oct 26 4:00 PM ET · prev $4.02
1 year
−56.3%
from $12.00 · Oct 27
30 days
−58.1%
from $12.50
52-week range
$4.02–14.69
−64% from high · low Oct 22
Avg volume 20D
3.6K
Oct 12 spike 27.1K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • TrendDOWNTREND

    53% below its 50-day average. New closing low $4.02 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & CODOUBLED16,853$201.9K

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Trading halt
Halt Resumed: BKHAU — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-22T18:14:15.000Z | Resumed 2026-10-22T18:24:15.000Z
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — DOUBLED
16,853 shares ($201.9K)
May 8, 2026 SEC
Black Hawk Acquisition Corp., a SPAC, issued a convertible promissory note to its sponsor for up to $300,000 at 10%…
8-K — Impact 2/10
Mar 18, 2026 Press
Vesicor Therapeutics, the proposed de-SPAC merger target of Black Hawk Acquisition Corp. (BKHAU), has appointed…
Impact 4/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

SecBot reports

1 filing · 1 press release · 0 bullish · 0 bearish · 1 neutral
All BKHAU filing & press-release reports (2)